Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Butylscopolamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 7/20 | 0.98 |
| ▸ | CHRM1 known ✓ | P11229 | 5/20 | 0.98 |
| ▸ | CHRM5 known ✓ | P08912 | 5/20 | 0.78 |
| ▸ | CHRM4 known ✓ | P08173 | 3/20 | 0.76 |
| ▸ | CHRM3 known ✓ | P20309 | 3/20 | 0.76 |
| ▸ | BLM | P54132 | 5/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 4/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butylscopolamine SCHEMBL1650352 | 1.00 | BLM (1.00) | BLMPMP22LMNACHRM2CHRM1 | |
| Butylscopolamine SCHEMBL29373202 | 1.00 | BLM (1.00) | BLMPMP22LMNACHRM2CHRM1 | |
| Butylscopolamine SCHEMBL25292 | 1.00 | BLM (1.00) | BLMPMP22LMNACHRM2CHRM1 | |
| Butylscopolamine SCHEMBL2441812 | 1.00 | BLM (1.00) | BLMPMP22LMNACHRM2CHRM1 | |
| Butylscopolamine SCHEMBL5028833 | 0.99 | BLM (0.98) | BLMPMP22LMNACHRM2CHRM1 | |
| Butylscopolamine SCHEMBL16168163 | 0.99 | CHRM2 (1.00) | BLMPMP22LMNACHRM2CHRM1 | |
| Butylscopolamine SCHEMBL29643439 | 0.99 | CHRM2 (1.00) | BLMPMP22LMNACHRM2CHRM1 | |
| Butylscopolamine SCHEMBL2446869 | 0.99 | CHRM2 (1.00) | BLMPMP22LMNACHRM2CHRM1 | |
| Butylscopolamine SCHEMBL14672547 | 0.99 | CHRM2 (1.00) | BLMPMP22LMNACHRM2CHRM1 | |
| Butylscopolamine SCHEMBL29473416 | 0.99 | CHRM2 (1.00) | BLMPMP22LMNACHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3372 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| US-12582601-B2 | Orodispersible powder composition | BIOPHARMA SYNERGIES, S.L. (ES) | 2026-03-24 | — | — | US | claimed |
| US-20260069687-A1 | THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER | ASTELLAS PHARMA INC (JP) | 2026-03-12 | — | — | US | claimed |
| EP-4680203-A1 | COMPOSITIONS FOR SUSTAINED RELEASE OF POORLY SOLUBLE ACTIVE INGREDIENTS | Prolevi Bio AB (SE) | 2026-01-21 | — | — | EP | claimed |
| EP-4154879-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NICOTINE WITHDRAWAL SYMPTOMS | KOREA INST SCI & TECH (KR) | 2025-09-10 | — | — | EP | claimed |
| US-20250248940-A1 | Biopolymer Formulations for Drug Delivery | 11584022 CANADA INC. (CA) | 2025-08-07 | — | — | US | claimed |
| EP-4547280-A1 | BIOPOLYMER FORMULATIONS FOR DRUG DELIVERY | 11584022 Canada Inc. (CA) | 2025-05-07 | — | — | EP | claimed |
| EP-4467974-A1 | NOVEL CHEMOSENSORS AND THEIR USE IN ELECTROCHEMICAL DETECTION METHODS | Karlsruher Institut für Technologie (DE) | 2024-11-27 | — | — | EP | claimed |
| US-20240366502-A1 | ORODISPERSIBLE POWDER COMPOSITION | BIOPHARMA SYNERGIES, S.L. (ES) | 2024-11-07 | — | — | US | claimed |
| WO-2024189127-A1 | COMPOSITIONS FOR SUSTAINED RELEASE OF POORLY SOLUBLE ACTIVE INGREDIENTS | PROLEVI BIO AB (SE) | 2024-09-19 | — | — | WO | claimed |
| EP-1015562-A1 | MODIFICATION OF POLYSACCHARIDES | D.J. VAN DER HAVE B.V. (NL) | 2000-07-05 | — | — | EP | claimed |
| WO-1999056698-A2 | TREATMENT OF CELIAC DISEASE | Københavns Universitet (DK) | 1999-11-11 | — | — | WO | claimed |
| EP-0945508-A1 | The insect-resistant use of sweet potato sporamin gene and method for controlling pests using the gene | NATIONAL SCIENCE COUNCIL (TW) | 1999-09-29 | — | — | EP | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5779661-A | Method of treating dysfunctional bladder syndromes by electromotive drug administration | PHYSION, S.R.L. (IT) | 1998-07-14 | — | — | US | claimed |
| CN-1185178-A | Recombinant preduodenal lipases and polypeptide derivatives produced by plant, prodn. and use thereof | JOUVEINAL SA (FR) | 1998-06-17 | — | — | CN | claimed |
| US-5700410-A | Method of manufacturing wax matrices | NIPPON SHINYAKU CO., LTD. (JP) | 1997-12-23 | — | — | US | claimed |
| WO-1997029186-A1 | MODIFICATION OF POLYSACCHARIDES | D.J. VAN DER HAVE B.V. (NL) | 1997-08-14 | — | — | WO | claimed |
| EP-0193056-B1 | COMBINATION OF FLUPIRTIN WITH SPASMOLYTICS HAVING AN ANTICHOLINERGIC EFFECT | ASTA Pharma Aktiengesellschaft (DE) | 1989-06-07 | — | — | EP | claimed |
| US-4668684-A | Combination of flupirtin and anticholinergic acting spasmolytic | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1987-05-26 | — | — | US | claimed |